Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.

What symbol and exchange does Kyntra Bio shares trade?

Kyntra Bio trades on the NASDAQ stock market under the symbol KYNB.

What is Kyntra Bio stock price doing today?

As of November 6, 2026, KYNB stock price climbed to $3.73 with 14,441 million shares trading.

What is Kyntra Bio's Beta?

KYNB has a beta of 1.43, meaning it tends to be more sensitive to market movements. KYNB has a correlation of 0.12 to the broad based SPY ETF.

How much is Kyntra Bio worth?

KYNB has a market cap of $15.09 million. This is considered a Sub-Micro Cap stock.

How much money does Kyntra Bio make?

Last quarter Kyntra Bio reported $-1 million in Revenue and -$4.68 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$1.50.

What are the top ETFs holding Kyntra Bio?

The top ETF exchange traded funds that KYNB belongs to (by Net Assets): VTI, VXF.

What are the support and resistance levels for Kyntra Bio (KYNB)?

KYNB support price is $3.42 and resistance is $3.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KYNB shares will trade within this expected range on the day.